openPR Logo
Press release

Download Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022 Report

09-14-2017 11:50 AM CET | Health & Medicine

Press release from: Kuick Resarch

Download Global Oncolytic Virus Therapy Market and Pipeline

“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials
.
The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. Thousands of regimens have been employed for the eradication of this deadly disease and yet the new interventions are anticipated. Undeniably, several modalities have resulted in some form of relief so far, but the triumph towards cancer abolition is long way road.

The conventional chemotherapy and radiotherapy have limited therapeutic index and a plethora of treatment associated negative effects. The current scenario of the oncological treatment represents the impetus search for the novel therapeutic modalities that can selectively disrupt the tumor cells and block the cancer growth along with the safety, that the treatment will be harmless towards the normal cells.

The major role of developing the new therapy for the treatment of cancer is to have broader therapeutic index which represents the high potency towards the malignant cells with low or no toxicities towards healthy cells. One such approach is the use of the viruses for the treatment of cancer turning into term known as viral oncotherapy. With the advances in oncology and the virology, the routes towards the engineering of viruses with increased tumor selectivity and enhanced oncolytic activity is conceivable.

Therefore the oncolytic virus is a virus that preferentially infects and kills cancer cells, as the infected cancer cells are destroyed by oncolysis, they release new infectious viral particles to help destroy the remaining tumor. Oncolytic viruses perform the dual functions they not only cause the destruction of cancerous cell but also stimulate the host anti-tumor immune responses and don’t allow the growth of tumor cells. Certainly, targeted therapy of cancer using viruses has generated interest in the light of limited efficacy of the standard cancer therapeutics.

The next few years will see progress in terms of viral delivery, in particular the use of immune cell carriers that have yet to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combinations of viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies will probably be tested in early phase clinical trials.

For the broader future of oncolytic immunotherapy, it is expected that a rapid expansion of the number of clinical trials already being conducted combining this with immune co-inhibitory pathway blockade, improved oncolytic agents being developed (i.e. with greater direct antitumor effects and with an improved ability to spread through tumors), and in particular the ability of viruses to deliver proteins directly to the tumor microenvironment to help further induce, enhance, and shape the anti-tumor immune response being exploited to a greater extent.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report--global-oncolytic-virus-therapy-market-and-pipeline-outlook-2022.php

Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics

Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting

Mechanism Involved in Viral Oncolysis
3.1 Viral Entry into Cancerous Cells
3.2 Efficacy Routes Followed by Oncogenic Viruses
3.3 Mechanism of Tumor Specificity
3.3.1 Defective Anti-Viral Responses
3.3.2 Receptor Targeting for Tumor Selective Intake
3.3.3 Targeting to Tumor Specific Promoters
3.3.4 Viral Gene Deletions
3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment

Cancer Immunotherapy by Oncolytic Viruses
4.1 Stimulation of Antitumor Immune Responses
4.2 Oncolytic Viruses as Cancer Vaccines

Varieties of Viruses Casted as Oncolytic Viruses
5.1 Oncolytic Wild Type Viruses
5.1.1 Reovirus (Respiratory Enteric Orphan Virus)
5.1.2 Vesicular Stomatitis Virus (VSV)
5.1.3 Newcastle Disease Virus (NDV)
5.1.4 Myxoma
5.2 Genetically Engineered Oncolytic Viruses
5.2.1 Adenoviruses
5.2.2 Herpes Simplex Virus
5.2.3 Vaccinia Virus

Approved Oncolytic Virus Therapeutics
6.1 Onxy-15
6.2 RIGVIR
6.3 Talimogene laherparepvec (T-VEC)
6.4 Reolysin

Potential Oncolytic Viruses for Cancers
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Melanoma
7.5 Brain Tumor
7.6 Blood Cancer

Global Oncolytic Virus Therapy Market Overview
8.1 Preface towards Oncolytic Virus Arcade
8.2 Market Aspects of Approved Oncolytic Viruses
8.3 Oncolytic Virus Clinical Pipeline Overview

Oncolytic Virus Market Dynamics
9.1 Accelerative Parameters
9.2 Major Challenges Faced by Oncolytic Virus

Future Aspects of Oncolytic Viral Therapy

Global Oncolytic Virus Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III

Marketed Oncolytic Virus Clinical Insight by Company and Indication
12.1 Talimogene Laherparepvec (IMLYGIC)
12.2 H 101 (Oncorine)

No Development Reported Oncolytic Virus Clinical Insight by Company, Indication and Phase
13.1 No Development Reported
13.2 Discontinued

Competitive Landscape
14.1 BioVex
14.2 Cell Genesys
14.3 Crusade Laboratories
14.4 Genelux Corporation
14.5 Jennerex Biotherapeutics
14.6 Lokon Pharma
14.7 Merck
14.8 MultiVir
14.9 Oncolys BioPharma
14.10 Oncolytics Biotech
14.11 Oncos Therapeutics
14.12 PsiOxus Therapeutics
14.13 Shanghai Sunway Bioteh
14.14 Takara Bio
14.15 VCN Biosciences
14.16 ViroTarg
14.17 Vyriad

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Download Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022 Report here

News-ID: 716682 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Virus

Zika Virus Vaccines Market 2022 | High rate of incidence of active Zika virus in …
Zika Virus Vaccines Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $18,697 million by 2022, registering a CAGR of 5.2% during the forecast period 2017-2022.Key opportunities include the need for vaccines for immunization & prevention of further spread of Zika virus infection and for treatment of Zika-linked birth defects. Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/1817 The outbreak of Zika virus infection in Latin
Viral Disease Diagnosis Market - Revolutionary Trends 2025 | Cytomegalovirus, De …
Global Viral Disease Diagnosis Market: Snapshot Thousands of deaths are occurring on a yearly basis on account of various viral infectious diseases. Some of the viral diseases occurring are rabies, avian influenza, HIV-1, measles, enterovirus, poliovirus, coronavirus, and Metapneumovirus. This has resulted in global public health concerns. Common influenza, contagious infections, and serious pandemics are some of the issues that need clinical prognosis for an early detection of the infectious agent.
Viral Disease Diagnosis Market to See Huge Growth by 2025 | Measles Virus, Polio …
Global Viral Disease Diagnosis Market: Snapshot Thousands of deaths are occurring on a yearly basis on account of various viral infectious diseases. Some of the viral diseases occurring are rabies, avian influenza, HIV-1, measles, enterovirus, poliovirus, coronavirus, and Metapneumovirus. This has resulted in global public health concerns. Common influenza, contagious infections, and serious pandemics are some of the issues that need clinical prognosis for an early detection of the infectious agent.
Virus Free Corporate Training
Interaction for learning is critical but our customers are slowly starting to realise that this doesn’t necessarily need to take place face to face. Virtual instructor led training (VILT) makes learning more accessible by removing geographical barriers. It helps improve user product adoption, knowledge and career development and eliminates the need for costly and time-consuming travel. Still, there’s often a misconception that in person training is the only type of
Tick-borne Encephalitis Inactivated Vaccine Market Report 2018: Segmentation by …
Global Tick-borne Encephalitis Inactivated Vaccine market research report provides company profile for Pfizer Inc., Encephalitis Global, Inc., The Cochrane Collaboration, Sonic HealthPlus Pty Ltd., Superdrug Health Clinic, GlaxoSmithKline plc, Merck & Co., Inc., Baxter International Inc., London Travel Clinic and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of
Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Deve …
"The Latest Research Report Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It provides comprehensive information on the therapeutics under development and key players involved